实践中使用IV纳西他马布治疗复发性/阻断性神经母细胞瘤儿童
Iris Fried1, Michael Weintraub1, Dalia Waldman2
1Pediatric Hematology Oncology unit, Shaare Tzedek medical center, Jerusalem, Israel.
Journal of pediatric hematology/oncology
|July 24, 2025
概括
针对抗GD2抗体的简化疼痛管理Naxitamab是可行的使用胺. 这种方法有效地控制了Naxitamab输注期间的疼痛,并减少了严重的不良反应,从而提高了患者的安全性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
背景情况:
- 纳西他马布是一种抗GD2抗体,由于显著的不良反应 (AE),需要复杂的疼痛管理.
- 现有的Naxitamab管理协议涉及复杂的止痛策略.
- 对于纳西他马布输注,需要简化和有效的疼痛管理协议.
研究的目的:
- 评估纳西他马布输注简化疼痛管理协议的安全性和可行性.
- 为了评估胺作为Naxitamab的唯一止痛药的有效性.
- 用简化方案确定输液相关不良事件的发生率.
主要方法:
- 一项对2021年11月至2023年7月期间进行的102次纳西他马布输注的回顾性审查.
- 胺被用作Naxitamab输注期间的独家止痛剂.
- 系统监测不良事件和疼痛控制.
主要成果:
- 在所有102次Naxitamab输注中,疼痛得到了有效控制.
- 3-4级不良事件发生在10%的输液中 (10/102).
- 由于输液相关的不良事件,没有患者停止使用Naxitamab;晚发的不良事件是罕见的.
结论:
- 单剂胺是一种安全有效的选择,用于管理纳西他马布输液相关的疼痛.
- 简化的胺协议可用于各种临床环境.
- 在第三个治疗周期后,与输液相关的重大不良事件很少发生.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
07:50Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
8.4K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drug Delivery: Parenteral Route
841
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
841
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
262
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
262
